Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France.

Abstract:

:Double cord blood transplantation extends the use of cord blood to adults for whom a single unit is not available, but the procedure is limited by its cost. To evaluate outcomes and cost-effectiveness of double compared to single cord blood transplantation, we analyzed 134 transplants in adults with acute leukemia in first remission. Transplants were performed in France with reduced intensity or myeloablative conditioning regimens. Costs were estimated from donor search to 1 year after transplantation. A Markov decision analysis model was used to calculate quality-adjusted life-years and cost-effectiveness ratio within 4 years. The overall survival at 2 years after single and double cord blood transplants was 42% versus 62%, respectively (P=0.03), while the leukemia-free-survival was 33% versus 53%, respectively (P=0.03). The relapse rate was 21% after double transplants and 42% after a single transplant (P=0.006). No difference was observed for non-relapse mortality or chronic graft-versus-host-disease. The estimated costs up to 1 year after reduced intensity conditioning for single and double cord blood transplantation were € 165,253 and €191,827, respectively. The corresponding costs after myeloablative conditioning were € 192,566 and € 213,050, respectively. Compared to single transplants, double cord blood transplantation was associated with supplementary costs of € 21,302 and € 32,420 up to 4 years, but with increases in quality-adjusted life-years of 0.616 and 0.484, respectively, and incremental cost-effectiveness ratios of € 34,581 and €66,983 in the myeloablative and reduced intensity conditioning settings, respectively. Our results showed that for adults with acute leukemia in first complete remission in France, double cord transplantation is more cost-effective than single cord blood transplantation, with better outcomes, including quality-adjusted life-years.

journal_name

Haematologica

journal_title

Haematologica

authors

Labopin M,Ruggeri A,Gorin NC,Gluckman E,Blaise D,Mannone L,Milpied N,Yakoub-Agha I,Deconinck E,Michallet M,Fegueux N,Socié G,Nguyen S,Cahn JY,de Revel T,Garnier F,Faucher C,Taright N,Kenzey C,Volt F,Bertrand D,M

doi

10.3324/haematol.2013.092254

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

535-40

issue

3

eissn

0390-6078

issn

1592-8721

pii

haematol.2013.092254

journal_volume

99

pub_type

杂志文章
  • The role of lactadherin in the phagocytosis of phosphatidylserine-expressing sickle red blood cells by macrophages.

    abstract::Lactadherin is a phosphatidylserine-binding glycoprotein secreted by macrophages. Less than 0.5% of normal circulating red cells showed any binding to lactadherin. However, the red cells from patients with sickle cell disease showed 2 to 10-fold increases in lactadherin binding. Further, lactadherin stimulated the pha...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Dasgupta SK,Thiagarajan P

    更新日期:2005-09-01 00:00:00

  • Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders.

    abstract::Daily intravenous arsenic trioxide administered with all-trans retinoid acid, the standard-of-care for acute promyelocytic leukemia, is costly and challenging to administer. ORH-2014 is a novel, oral arsenic trioxide formulation, consisting of micron-size drug particles with rapid dissolution and high bioavailability....

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.229583

    authors: Ravandi F,Koumenis I,Johri A,Tallman M,Roboz GJ,Strickland S,Garcia-Manero G,Borthakur G,Naqvi K,Meyer M,Pudipeddi M,Nidarmarthy S,Vaddi K,Kantarjian H

    更新日期:2020-06-01 00:00:00

  • Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

    abstract::The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic myeloid leukemia p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2016.144949

    authors: Castagnetti F,Breccia M,Gugliotta G,Martino B,D'Adda M,Stagno F,Carella AM,Avanzini P,Tiribelli M,Trabacchi E,Visani G,Gobbi M,Salvucci M,Levato L,Binotto G,Capalbo SF,Bochicchio MT,Soverini S,Cavo M,Martinelli G,

    更新日期:2016-10-01 00:00:00

  • Combined modality therapy in advanced Hodgkin's disease: a report on 218 patients with a median follow-up of eight years.

    abstract:BACKGROUND AND OBJECTIVE:This study was designed to evaluate the efficacy and toxicity of monthly alternating ABVD/MOPP compared to ABVD/OPP regimens in patients with advanced stage Hodgkin's disease (HD), as well as in early stage patients with systemic symptoms and/or bulky disease. DESIGN AND METHODS:218 patients w...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Anselmo AP,Cavalieri E,Enrici RM,Donato V,Pescarmona E,Biagini C,Mandelli F

    更新日期:1998-07-01 00:00:00

  • Recurrent mutations in the iron regulatory element of L-ferritin in hereditary hyperferritinemia-cataract syndrome.

    abstract:BACKGROUND AND OBJECTIVE:Hereditary hyperferritinemia-cataract syndrome (HHCS) is an autosomal dominant disorder characterized by bilateral cataracts and increased serum and tissue L-ferritin, in the absence of iron overload. The deregulation of ferritin production is caused by heterogeneous mutations in the iron regul...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Cicilano M,Zecchina G,Roetto A,Bosio S,Infelise V,Stefani S,Mazza U,Camaschella C

    更新日期:1999-06-01 00:00:00

  • Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.

    abstract:BACKGROUND AND OBJECTIVES:Transplant-related mortality (TRM) following allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to be related to disease stage, duratiion of disease and type of donor. Furthermore, the outcome of transplants performed in the 1990s appears to be better than that of tran...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Bacigalupo A,Sormani MP,Lamparelli T,Gualandi F,Occhini D,Bregante S,Raiola AM,di Grazia C,Dominietto A,Tedone E,Piaggio G,Podesta M,Bruno B,Oneto R,Lombardi A,Frassoni F,Rolla D,Rollandi G,Viscoli C,Ferro C,Garba

    更新日期:2004-10-01 00:00:00

  • Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.

    abstract::Iron overload and hepatitis virus C infection cause liver fibrosis in thalassemics. In a monocentric retrospective analysis of liver disease in a cohort of 191 transfusion-dependent thalassemics, in 126 patients who had undergone liver biopsy (mean age 17.2 years; 58 hepatitis virus C-RNA positive and 68 hepatitis vir...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12554

    authors: Di Marco V,Capra M,Gagliardotto F,Borsellino Z,Cabibi D,Barbaria F,Ferraro D,Cuccia L,Ruffo GB,Bronte F,Di Stefano R,Almasio PL,Craxì A

    更新日期:2008-08-01 00:00:00

  • Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias.

    abstract:BACKGROUND AND OBJECTIVES:Levels of intracellular bcl-2 oncoprotein have been found to be increased in leukemic cells of CD5+ B-chronic lymphocytic leukemia (CLL) patients. However, it is not clear whether bcl-2 overexpression is a peculiar feature of CD5+ B-CLL. Based on this background we carried out a quantitative f...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Molica S,Mannella A,Crispino G,Dattilo A,Levato D

    更新日期:1997-09-01 00:00:00

  • Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.

    abstract::Acquired aplastic anemia is an immune-mediated disease characterized by severe defects in stem cell number resulting in hypocellular marrow and peripheral blood cytopenias. Minor paroxysmal nocturnal hemoglobinuria populations and a short telomere length were identified as predictive biomarkers of immunosuppressive th...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2015.132530

    authors: Narita A,Muramatsu H,Sekiya Y,Okuno Y,Sakaguchi H,Nishio N,Yoshida N,Wang X,Xu Y,Kawashima N,Doisaki S,Hama A,Takahashi Y,Kudo K,Moritake H,Kobayashi M,Kobayashi R,Ito E,Yabe H,Ohga S,Ohara A,Kojima S,Japan Ch

    更新日期:2015-12-01 00:00:00

  • Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.

    abstract::Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognostic parameter in patients younger than 66 years treated homogeneously with intensive approaches is unknown. To address this...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.098608

    authors: Chretien ML,Hebraud B,Cances-Lauwers V,Hulin C,Marit G,Leleu X,Karlin L,Roussel M,Stoppa AM,Guilhot F,Lamy T,Garderet L,Pegourie B,Dib M,Sebban C,Lenain P,Brechignac S,Royer B,Wetterwald M,Legros L,Orsini-Piocelle

    更新日期:2014-07-01 00:00:00

  • Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation.

    abstract:BACKGROUND AND OBJECTIVES:Although several studies have reported on the use of children as donors for peripheral blood progenitor cells (PBPC), no specific characteristics have been identified as predictors of PBPC collection in this population. In this study we analyzed predictive factors for PBPC collection in pediat...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Díaz MA,Sevilla J,de la Rubia J,Verdeguer A,Espigado I,Vicent MG,Pascual MJ,Zamora C,Arrieta R,Serrano D,del Cañizo C,Arbona C,de Arriba F,Bargay J,Brunet S,Sanz MA

    更新日期:2003-08-01 00:00:00

  • MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response.

    abstract:BACKGROUND:MicroRNAs can play an important role in tumorigenesis through post-transcriptional regulation of gene expression, and are not well characterized in follicular lymphoma. DESIGN AND METHODS:MicroRNA profiles of enriched follicular lymphoma tumor cells from 16 patients were generated by assaying 851 human micr...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.048132

    authors: Wang W,Corrigan-Cummins M,Hudson J,Maric I,Simakova O,Neelapu SS,Kwak LW,Janik JE,Gause B,Jaffe ES,Calvo KR

    更新日期:2012-04-01 00:00:00

  • Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

    abstract::Here we critically evaluate the role of elevated hematocrit as the principal determinant of thrombotic risk in polycythemia and erythrocytosis, defined by an expansion of red cell mass. Since red cell volume determination is no longer readily available, in clinical practice, polycythemia and erythrocytosis are defined...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.2018.210732

    authors: Gordeuk VR,Key NS,Prchal JT

    更新日期:2019-04-01 00:00:00

  • Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.

    abstract::We studied wild-type FLT3 mRNA expression at diagnosis in bone marrow samples from 85 patients with acute myeloid leukemia (AML), 23 of whom were in complete remission, and determined its utility as a marker for minimal residual disease (MRD). We conclude that FLT3 expression is of limited value as a prognostic marker...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Kainz B,Fonatsch C,Schwarzinger I,Sperr WR,Jäger U,Gaiger A

    更新日期:2005-05-01 00:00:00

  • Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial.

    abstract:BACKGROUND:In recent years many therapeutic regimens have been designed in order to improve response rate and response duration in non-Hodgkin's lymphoma (NHL). In 1991 the Italian Lymphoma Study Group (GISL) started a prospective randomized trial on treatment of aggressive and advanced NHL, focused on the efficacy of ...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Brugiatelli M,Federico M,Gobbi PG,Avanzini P,Callea V,Cavanna L,De Pasquale A,Di Prisco AU,Di Rienzo N,Silingardi V

    更新日期:1993-09-01 00:00:00

  • Neurological disorders in essential thrombocythemia.

    abstract::Patients with essential thrombocythemia often complain of various subjective neurological symptoms. This prospective study aims to assess their incidence and response to therapy. Among 37 consecutive patients with essential thrombocythemia, 11 presented with neurological symptoms. Among them 4 had thrombotic events, 7...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2011.050005

    authors: Billot S,Kouroupi EG,Le Guilloux J,Cassinat B,Jardin C,Laperche T,Fenaux P,Carpentier AF,Kiladjian JJ

    更新日期:2011-12-01 00:00:00

  • Incidence and clinicopathological heterogeneity of HIV-related non-Hodgkin's lymphoma.

    abstract::The characteristics of 14 HIV-seropositive patients with NHL consecutively observed between 1984 and 1988 at our Institution are described. Patients belonged to a known population of 1242 HIV-seropositive individuals in whom the incidence of NHL was 1.13%, significantly higher than in age-matched controls (P less than...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Rossi G,Cadeo G,Stellini R,Zorzi F,Favret M,Sueri L,Carosi G,Mariano M,Marinone G

    更新日期:1990-05-01 00:00:00

  • Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.

    abstract:BACKGROUND AND OBJECTIVES:To assess the efficacy and the toxic profile of gemcitabine, a novel pyrimidine antimetabolite active against several solid tumors, we carried out a study in heavily pretreated Hodgkin's disease (HD) patients. DESIGN AND METHODS:From May 1997 to January 1999, 14 pretreated patients (10 relaps...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Zinzani PL,Bendandi M,Stefoni V,Albertini P,Gherlinzoni F,Tani M,Piccaluga PP,Tura S

    更新日期:2000-09-01 00:00:00

  • Transcriptional activation of the cardiac homeobox gene CSX1/NKX2-5 in a B-cell chronic lymphoproliferative disorder.

    abstract::Homeobox containing transcription factors are frequently deregulated in human hematologic malignant diseases either indirectly through an abnormality of an upstream factor, or directly through rearrangement of the gene itself. Study of T-cell acute lymphoblastic leukemia identified the related non-clustered homeobox t...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12595

    authors: Su X,Della-Valle V,Delabesse E,Azgui Z,Berger R,Merle-Béral H,Bernard OA,Nguyen-Khac F

    更新日期:2008-07-01 00:00:00

  • Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.

    abstract::Although myelodysplastic syndromes are heterogeneous disorders comprising a benign subset of bone marrow failure similar to aplastic anemia, no laboratory test has been established to distinguish it from bone marrow failures that can evolve into acute myeloid leukemia. Plasma thrombopoietin levels were measured in 120...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.066217

    authors: Seiki Y,Sasaki Y,Hosokawa K,Saito C,Sugimori N,Yamazaki H,Takami A,Nakao S

    更新日期:2013-06-01 00:00:00

  • Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.

    abstract:BACKGROUND:The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis - acute myeloid leukemia with myelodysplasia-related changes (≥20% myeloblasts of all nucleated c...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.043687

    authors: Bacher U,Haferlach C,Alpermann T,Kern W,Schnittger S,Haferlach T

    更新日期:2011-09-01 00:00:00

  • Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.

    abstract::Systemic AL amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly but treatment and outcomes have not been systematically studied in this group of patients in whom comorbidities and frailty may compound morbidity and mortality. We report the outcomes of 295 pat...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2015.128025

    authors: Sachchithanantham S,Offer M,Venner C,Mahmood SA,Foard D,Rannigan L,Lane T,Gillmore JD,Lachmann HJ,Hawkins PN,Wechalekar AD

    更新日期:2015-11-01 00:00:00

  • Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma.

    abstract:BACKGROUND:The c-Met signaling pathway regulates a variety of biological processes, including proliferation, survival and migration. Deregulated c-Met activation has been implicated in the pathogenesis and prognosis of many human malignancies. We studied the function and prognostic significance of c-Met and hepatocyte ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.056101

    authors: Xu C,Plattel W,van den Berg A,Rüther N,Huang X,Wang M,de Jong D,Vos H,van Imhoff G,Viardot A,Möller P,Poppema S,Diepstra A,Visser L

    更新日期:2012-04-01 00:00:00

  • T-cell receptor repertoire usage after allografting differs between CD4+CD25+ regulatory T cells and their CD4+CD25- counterpart.

    abstract:BACKGROUND AND OBJECTIVES:After allogeneic haematopoietic stem cell transplantation (SCT) the whole T-cell receptor (TCR) repertoire shows a markedly skewed pattern for 2-3 years. A small fraction of CD4+ T cells is represented by CD25+ regulatory lymphocytes (Treg), which play a crucial role in modulating peripheral t...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.10774

    authors: Fozza C,Nadal E,Longinotti M,Dazzi F

    更新日期:2007-02-01 00:00:00

  • High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.

    abstract::Indoleamine 2,3-dioxygenase degrades the amino acid tryptophan which is essential for T cells. Tryptophan depletion causes T-cell cycle arrest and solid tumors that express high levels of indoleamine 2,3-dioxygenase can create immune suppression. Recently, blasts of patients with acute myeloid leukemia were shown to e...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.13113

    authors: Chamuleau ME,van de Loosdrecht AA,Hess CJ,Janssen JJ,Zevenbergen A,Delwel R,Valk PJ,Löwenberg B,Ossenkoppele GJ

    更新日期:2008-12-01 00:00:00

  • Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.

    abstract:BACKGROUND:Hematocrit above the normal range for the population, such as in primary or secondary erythrocytosis, predisposes to both arterial and venous thrombosis. However, little is known about the association between hematocrit and risk of venous thromboembolism in a general population. DESIGN AND METHODS:Hematocri...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.008417

    authors: Braekkan SK,Mathiesen EB,Njølstad I,Wilsgaard T,Hansen JB

    更新日期:2010-02-01 00:00:00

  • Progression to acquired immunodeficiency syndrome in 94 human immunodeficiency virus-positive hemophiliacs with long-term follow-up.

    abstract:BACKGROUND AND OBJECTIVES:Human immunodeficiency virus (HIV) infection was transmitted to many hemophilics treated with non-inactivated factor concentrates before 1986. The aim of this study was to know the long-term incidence of AIDS and risk factors for its development in HIV-infected hemophiliacs. DESIGN AND METHOD...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Lorenzo JI,Moscardó F,López-Aldeguer J,Aznar JA

    更新日期:2001-03-01 00:00:00

  • Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.

    abstract::The introduction of agents inhibiting the BCR-associated kinases such as ibrutinib has dramatically changed treatments algorithms of chronic lymphocytic leukaemia (CLL) as well as the role of different adverse prognosticators. We evaluated the efficacy of ibrutinib as single agent, in a real-life context, on 180 patie...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2020.251488

    authors: Del Poeta G,Biagi A,Laurenti L,Chiarenza A,Pozzo F,Innocenti I,Postorino M,Rossi FM,Del Principe MI,Bomben R,de Fabritiis P,Bruno A,Cantonetti M,Di Raimondo F,Zucchetto A,Gattei V

    更新日期:2020-07-30 00:00:00

  • Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

    abstract:BACKGROUND:Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare th...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.019042

    authors: Pepe A,Meloni A,Capra M,Cianciulli P,Prossomariti L,Malaventura C,Putti MC,Lippi A,Romeo MA,Bisconte MG,Filosa A,Caruso V,Quarta A,Pitrolo L,Missere M,Midiri M,Rossi G,Positano V,Lombardi M,Maggio A

    更新日期:2011-01-01 00:00:00

  • In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

    abstract::Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells ex...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2014.111740

    authors: Angelot-Delettre F,Roggy A,Frankel AE,Lamarthee B,Seilles E,Biichle S,Royer B,Deconinck E,Rowinsky EK,Brooks C,Bardet V,Benet B,Bennani H,Benseddik Z,Debliquis A,Lusina D,Roussel M,Solly F,Ticchioni M,Saas P,Garna

    更新日期:2015-02-01 00:00:00